Search Results - "Bizzini, B"

Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases by Zagury, D, Le Buanec, H, Bizzini, B, Burny, A, Lewis, G, Gallo, R.C

“…Current therapeutic vaccine trials in major chronic diseases including AIDS, cancer, allergy and autoimmunity, target antigenic pathogens but not the…”
Get full text

Adjuvants--a balance between toxicity and adjuvanticity by Gupta, R K, Relyveld, E H, Lindblad, E B, Bizzini, B, Ben-Efraim, S, Gupta, C K

“…Adjuvants have been used to augment the immune response in experimental immunology as well as in practical vaccination for more than 60 years. The chemical…”
Get more information

Procedures for preparing biologically inactive, but immunogenic HIV-1 Tat protein (Tat toxoid) for human use by Le Buanec, H., Bizzini, B.

“…Extracellular Tat can exercise its deleterious effects on cells surrounding HIV-1-infected cells and allow spreading of virus. Extracellular Tat should be…”
Get full text

Binding of HIV-1 to RBCs involves the Duffy Antigen Receptors for Chemokines (DARC) by Lachgar, A, Jaureguiberry, G, Le Buenac, H, Bizzini, B, Zagury, JF, Rappaport, J, Zagury, D

“…The Duffy Antigen Receptor for Chemokines (DARC) belongs to a family of erythrocyte chemokine receptors that bind C-X-C and C-C chemokines such as interleukin…”
Get full text

HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes by Le Buanec, H., D'Anna, R., Lachgar, A., Zagury, J.F., Bernard, J., Ittelé, D., d'Alessio, P., Hallez, S., Giannouli, C., Burny, A., Bizzini, B., Gallo, R.C., Zagury, D.

“…HPV-16 E6 and E7 oncoproteins impair the cell cycle in human uterine cervix carcinoma cells (HUCC) by acting on p53 and retinoblastoma proteins, respectively…”
Get full text

Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes by Le Buanec, H, Vetu, C, Lachgar, A, Benoît, M.A, Gillard, J, Paturance, S, Aucouturier, J, Gane, V, Zagury, D, Bizzini, B

“…Anti-Tat vaccination experiments were carried out in mice with a view to inducing systemic in addition to mucosal immunity. For this, three types of immunizing…”
Get full text

"Kinoids": the basis for anticytokine immunization and their use in HIV infection by Bizzini, B, Achour, A

“…HIV infection is characterized, at least in part, by the dysregulation of the cytokine network. Both IFN gamma and IFN alpha are occasionally overproduced…”
Get more information

Contribution of alpha interferon (alpha IFN) to HIV-induced immunosuppression by Lachgar, A, Bizzini, B

“…In the present investigation we have shown that PBLs taken from HIV-positive patients suppressed T-cell proliferation when cultured for at least 12 days. When…”
Get more information

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients by Gringeri, A, Santagostino, E, Muça-Perja, M, Mannucci, P M, Zagury, J F, Bizzini, B, Lachgar, A, Carcagno, M, Rappaport, J, Criscuolo, M, Blattner, W, Burny, A, Gallo, R C, Zagury, D

“…To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HIV-1 vaccine using…”
Get more information

Potentialization of IL-2 effects on immune cells by oyster extract (JCOE) in normal and HIV-infected individuals by Achour, A, Lachgar, A, Astgen, A, Chams, V, Bizzini, B, Tapiero, H, Zagury, D

“…Peripheral blood mononuclear cells (PBMCs) are physiologically activated by interleukin (IL)-2. We found that oyster extract (JCOE) currently used as a…”
Get full text

Use of xenogenized (modified) tumor cells for treatment in experimental tumor and in human neoplasia by Ben-Efraim, S., Bizzini, B., Relyveld, E.H.

“…The need to modify tumor cells in order to render them more “immunogenic” was based on the assumption that normal, nonmodified tumor cells are non or weakly…”
Get full text

Preparation of diphtheria vaccines using highly purified toxins by Relyveld, Edgar, Bizzini, Bernard, Huet, Maurice

“…We should like comment on the paper of Galazka and Robertson relative to diphtheria immunization. In their paper, the authors have readily overlooked papers by…”
Get full text

IFNα kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS by Bizzini, B., Volpato, I., Lachgar, A., Cohen, P., Gringeri, A.

“…Antiviral therapy, including antiprotease treatment, suppresses viral replication, but it does not restore the HIV-1 induced immunopathogenesis which includes…”
Get full text

Involvement of alpha-interferon in HIV-1 induced immunosuppression. A potential target for AIDS prophylaxis and treatment by Lachgar, A, Bizzini, B

“…Since the immune system is impaired in the course of HIV-infection, the purpose of any AIDS vaccine therapy should be the restoration in the patient of an…”
Get more information

Induction of cellular immunosuppression by the human papillomavirus type 16 E7 oncogenic protein by Le Buanec, H., Lachgar, A., D'Anna, R., Zagury, J.F., Bizzini, B., Bernard, J., Ittelé, D., Hallez, S., Giannouli, N., Burny, A., Zagury, D.

“…The human papillomavirus type 16 (HPV-16) E7 oncogenic protein is found in the culture supernatant of SiHa cells, a cervical carcinoma cell line. Extracellular…”
Get full text

Production in rabbits of high levels of anti-HIV-1 gp160 antibodies by Relyveld, E, Bizzini, B

“…The production of anti-HIV-1 gp160 antibodies was obtained in rabbits given gp160 either in saline or adsorbed onto calcium phosphate. Immunization with gp160…”
Get more information

Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum — an adjuvant to antiretroviral tritherapy by Zagury, D., Lecoq, H., Gervi, I., Le Buanec, H., Zagury, J.F., Bizzini, B., Burny, A., Hermans, P., Perja, M., Santagostino, E., Gringeri, A.

“…HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However, since the antiretroviral agents used in HAART may also…”
Get full text

Identification of CD4 and Major Histocompatibility Complex Functional Peptide Sites and Their Homology with Oligopeptides from Human Immunodeficiency Virus Type 1 Glycoprotein gp120: Role in AIDS Pathogenesis by Zagury, J. F., Bernard, J., Achour, A., Astgen, A., Lachgar, A., Fall, L., Carelli, C., Issing, W., Mbika, J. P., Picard, O., Charlotti, M., Callebaut, I., Mornon, J. P., Burny, A., Feldman, M., Bizzini, B., Zagury, D.

“…CD4 molecules interact with class II major histocompatibility complex molecules as a critical costimulatory signal in CD4+cell immune activation. CD4 also…”
Get full text

Lectin production by human T-lymphocytes by Lachgar, A., Buanec, H. Le, Burny, A., Bizzini, B., Zagury, D.

“…Cultured human peripheral blood monocytes (PBMC) and the cell line H9 release a lectin. This lectin is not the previously described sarcolectin, since it does…”
Get full text

A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat Toxoid by Le Buanec, H, Lachgar, A, Bizzini, B, Zagury, JF, Rappaport, J, Santagostino, E, Muça-Perja, M, Gringeri, A

“…Extracellular Tat can act as a viral toxin on uninfected cells of different tissues, including the CNS and the immune system, thus in order to immunize humans…”
Get full text